Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis.

What was studied

This was a review and pooled analysis in follicular lymphoma. The adults had advanced-stage disease with low tumor burden and no symptoms. The team compared rituximab alone with watchful waiting (WW). They searched PubMed, Embase and the Cochrane Library. The main outcome was overall survival (OS). Others were transformation and time to new treatment.

What they found

The studies were 2 trials and one observational study, with 1590 patients. OS did not differ between rituximab and WW. The hazard ratio was 0.89, with a range of 0.70-1.12. Transformation was not significantly reduced. Time to new treatment was significantly longer with rituximab. The hazard ratio was 0.50.

What it means for patients

The authors said early rituximab alone was not linked to better OS. They said it did not significantly cut transformation. It did prolong the time to new treatment. They said more prospective studies are needed to define long-term impact.

Why it is not certain yet

The review pooled few studies, and one was observational. Estimates for survival and transformation leaned a little toward rituximab, but not significantly. Long-term effects are unclear.

Source

Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.